FreeTheAI

Fractyl Health Study Shows Revita Procedure Helps Retain Weight Loss After GLP-1 Discontinuation

BullishHigh impact
GUTS$4.16 1.96%

Fractyl Health, Inc. (NASDAQ:GUTS) announced positive six-month results from the pivotal cohort of its REMAIN-1 study. The 308-participant clinical trial tested the Revita DMR System in adults with obesity who stopped GLP-1 weight-loss therapy. The study met its initial co-primary endpoint, showing that a single Revita procedure significantly reduced weight regain compared to a sham procedure.

Patients receiving the Revita treatment retained about 80% of their drug-induced weight loss after six months, compared to 67% in the control group. Additionally, 32% of Revita patients maintained a stable weight or lost further weight, compared to 18% in the sham group. The trial reported no device-related or procedure-related serious adverse events, and related side effects were mostly mild and temporary.

Fractyl Health plans to submit a De Novo marketing application to the U.S. Food and Drug Administration in late Q4 2026. A procedural coding update takes effect on January 1, 2027, followed by anticipated full 12-month study results in Q1 2027. If regulatory clearance is granted, the company envisions a commercial launch in the United States in early 2028.

Key points

  • Fractyl Health's REMAIN-1 trial met its six-month co-primary endpoint with high statistical significance.
  • Revita participants retained 80% of GLP-1 weight loss versus 67% for sham procedure participants at six months.
  • The trial reported no device-related or procedure-related serious adverse events as of September 2026.
  • Fractyl Health plans to submit an FDA De Novo application in late Q4 2026 and expects one-year study data in Q1 2027.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What were the main results of Fractyl Health's REMAIN-1 study?

Patients treated with Fractyl Health's Revita device maintained 80% of GLP-1 weight loss after six months compared to 67% for sham participants, meeting the study's six-month co-primary endpoint.

When does Fractyl Health plan to submit Revita to the FDA?

Fractyl Health plans to submit a De Novo marketing application for Revita to the U.S. Food and Drug Administration in late Q4 2026, with 12-month study results expected in Q1 2027.

Were there any safety concerns reported in the Revita study?

The study reported no device-related or procedure-related serious adverse events and no deaths. Side effects were mostly mild and occurred within seven days of the procedure.